Biohaven commences Phase 3 clinical trial for Graves' disease treatment

Biohaven has launched a Phase 3 pivotal clinical trial for BHV-1300, a candidate therapy targeting Graves' disease. The initiation of the study marks a significant development in the pursuit of new treatment options for a condition that has historically lacked recent regulatory approvals for therapeutic interventions.

Concurrent with the trial launch, the company presented three scientific posters at the 2026 American Thyroid Association (ATA) Annual Meeting. The presentations detailed the autoimmune mechanisms underlying the disease and outlined the functional application of the company's MoDE and TRAP technology platforms. These disclosures reflect an effort to improve the current understanding of patient symptom burdens and biological drivers of the condition.

Graves' disease remains a significant concern within endocrinology due to its prevalence and the limited efficacy of existing standard-of-care treatments. Biohaven’s research program aims to address these clinical gaps by utilizing targeted degradation approaches. The company expects the ongoing Phase 3 trial to provide critical data on the safety and efficacy of BHV-1300 in patient populations.